Neoadjuvant TCH (docetaxel/darboplatin/trastuzumab) versus EC-TH (epirubicin/cyclophosphamide followed by docetaxel/ trastuzumab ) in patients with HER2-positive breast cancer (neoCARH): A randomised, open-label, multicenter, phase II trial.

Hong-Fei Gao,Zhiyong Wu,Ying Lin,Xiangyang Song,Yin Cao,Zhenzhen Liu,Qian Jun-chen,Liu-Lu Zhang,Ci-Qiu Yang,Mei Yang,Teng Zhu,Jieqing Li,Fei Ji,Min-Yi Cheng,Kun Wang

Neoadjuvant TCH (docetaxel/darboplatin/trastuzumab) versus EC-TH (epirubicin/cyclophosphamide followed by docetaxel/ trastuzumab ) in patients with HER2-positive breast cancer (neoCARH): A randomised, open-label, multicenter, phase II trial.

2020

Hong-Fei Gao
Zhiyong Wu
Ying Lin
Xiangyang Song
Yin Cao
Zhenzhen Liu
Qian Jun-chen
Liu-Lu Zhang
Ci-Qiu Yang
Mei Yang
Teng Zhu
Jieqing Li
Fei Ji
Min-Yi Cheng
Kun Wang

585Background: The optimal neoadjuvant treatment for HER2-positive breast cancer is unknown. We wanted to compare the efficacy and safety of the anthracycline regimen EC-TH versus nonanthracycline ...

Keywords:

Internal medicine
Epirubicin
Trastuzumab
Oncology
Breast cancer
Regimen
Pathology
open label
Cyclophosphamide
Medicine
Docetaxel
Anthracycline

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations